Benzethonium chloride: A novel anticancer agent identified by using a cell-based small-molecule screen

Clinical Cancer Research

Volumn 12, Issue 18, 2006, Pages 5557-5569

  Yip, Kenneth W ^a,c   Mao, Xinliang ^c   Au, P Y Billie ^a,c   Hedley, David W ^a,c   Chow, Sue ^a,c   Dalili, Shadi ^b,c   Mocanu, Joseph D ^a,c   Bastianutto, Carlo ^a,c   Schimmer, Aaron ^a,c   Liu, Fei Fei ^a,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ALEXIDINE; ANTINEOPLASTIC AGENT; AZATHIOPRINE; BENZETHONIUM CHLORIDE; BENZOPORPHYRIN DERIVATIVE; BERBERINE; CANTHARIDIN; CASPASE; CISPLATIN; CLOFILIUM TOSYLATE; DEQUALINIUM; DIGITOXIGENIN; DIGOXIN; FENBENDAZOLE; FLUOROURACIL; INDATRALINE; IVERMECTIN; KETOCONAZOLE; LANATOSIDE C; LOPERAMIDE; METHYLBENZETHONIUM CHLORIDE; OUABAIN; PACLITAXEL; PROSCILLARIDIN; SANGUINARINE; STROPHANTHIN; TETRAZOLIUM; UNINDEXED DRUG; ZAPRINAST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; ENZYME ACTIVATION; FLOW CYTOMETRY; GAMMA IRRADIATION; HEAD AND NECK CANCER; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; HYPOPHARYNX CANCER; MOUSE; NASOPHARYNX CANCER; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SIDE EFFECT; TRANSMISSION ELECTRON MICROSCOPY; TUMOR GROWTH; WEIGHT REDUCTION; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZETHONIUM; CALCIUM; CASPASES; CELL PROLIFERATION; CELL SURVIVAL; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG THERAPY, COMBINATION; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MEMBRANE POTENTIALS; MICE; MICE, INBRED BALB C; MICE, SCID; MITOCHONDRIAL MEMBRANES; MODELS, BIOLOGICAL; NEOPLASMS; NIH 3T3 CELLS; RADIATION-SENSITIZING AGENTS; TISSUE ARRAY ANALYSIS; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33749319699     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-0536     Document Type: Article

References (50)

1. Stockwell BR. Chemical genetics: ligand-based discovery of gene function. Nat Rev Genet 2000;1:116-25.
2. Druker BJ, Lydon NB. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 2000;105:3-7.
3. Gleevec approved for first-line treatment of CML. FDA Consum 2003;37:5.
4. Dagher R, Cohen M, Williams G, et al. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res 2002;8:3034-8.
5. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004;305:399-401.
6. Pao W, Miller VA. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol 2005;23:2556-68.
7. Adams J, Behnke M, Chen S, et al. Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg Med Chem Lett 1998;8:333-8.
8. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004;351:1860-73.
9. Oltersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005;435:677-81.
10. Schimmer AD, Welsh K, Pinilla C, et al. Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity. Cancer Cell 2004;5:25-35.
11. Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 1971;93:2325-7.
12. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature 1979;277:665-7.
13. Liu J, Farmer JD, Jr., Lane WS, Friedman J, Weissman I, Schreiber SL. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 1991;66:807-15.
14. 1-arresting rapamycin-receptor complex. Nature 1994;369:756-8.
15. Holbeck SL. Update on NCI in vitro drug screen utilities. Eur J Cancer 2004;40:785-93.
16. Yip KW, Li A, Li JH, et al. Potential utility of BimS as a novel apoptotic therapeutic molecule. Mol Ther 2004;10:533-44.
17. Li AA, Ng E, Shi W, et al. Potential efficacy of p16 gene therapy for EBV-positive nasopharyngeal carcinoma. Int J Cancer 2004;110:452-8.
18. Chia MC, Shi W, Li JH, et al. A conditionally replicating adenovirus for nasopharyngeal carcinoma gene therapy. Mol Ther 2004;9:804-17.
19. Lee AW, Li JH, Shi W, et al. p16 gene therapy: a potentially efficacious modality for nasopharyngeal carcinoma. Mol Cancer Ther 2003;2:961-9.
20. Liu FF. Novel gene therapy approach for nasopharyngeal carcinoma. Semin Cancer Biol 2002;12:505-15.
21. Yip KW, Mocanu JD, Au PY, et al. Combination bcl-2 antisense and radiation therapy for nasopharyngeal cancer. Clin Cancer Res 2005;11:8131-44.
22. Schimmer AD, Hedley DW, Chow S, et al. The BH3 domain of BAD fused to the Antennapedia peptide induces apoptosis via its α helical structure and independent of Bcl-2. Cell Death Differ 2001;8:725-33.
23. Zhang JH, Chung TD, Oldenburg KR. A simple statistical parameter for use in evaluation and validation of high-throughput screening assays. J Biomol Screen 1999;4:67-73.
24. Vander Heiden MG, Chandel NS, Schumacker PT, Thompson CB. Bcl-xL prevents cell death following growth factor withdrawal by facilitating mitochondrial ATP/ADP exchange. Mol Cell 1999;3:159-67.
25. Pham NA, Hedley DW. Respiratory chain-generated oxidative stress following treatment of leukemic blasts with DNA-damaging agents. Exp Cell Res 2001;264:345-52.
26. Davis PD, Dougherty GJ, Blakey DC, et al. ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature. Cancer Res 2002;62:7247-53.
27. Petersen C, Zips D, Krause M, Volkel W, Thames HD, Baumann M. Recovery from sublethal damage during fractionated irradiation of human FaDu SCC. Radiother Oncol 2005;74:331-6.
28. Zips D, Krause M, Hessel F, et al. Experimental study on different combination schedules of VEGF-receptor inhibitor PTK787/ZK222584 and fractionated irradiation. Anticancer Res 2003;23:3869-76.
29. Berthold DR, Sternberg CN, Tannock IF. Management of advanced prostate cancer after first-line chemotherapy. J Clin Oncol 2005;23:8247-52.
30. Lui H, Hobbs L, Tope WD, et al. Photodynamic therapy of multiple nonmelanoma skin cancers with verteporfin and red light-emitting diodes: two-year results evaluating tumor response and cosmetic outcomes. Arch Dermatol 2004;140:26-32.
31. Efferth T, Rauh R, Kahl S, et al. Molecular modes of action of cantharidin in tumor cells. Biochem Pharmacol 2005;69:811-8.
32. Ahmad N, Gupta S, Husain MM, Heiskanen KM, Mukhtar H. Differential antiproliferative and apoptotic response of sanguinarine for cancer cells versus normal cells. Clin Cancer Res 2000;6:1524-8.
33. Daniel D, Susal C, Kopp B, Opelz G, Terness P. Apoptosis-mediated selective killing of malignant cells by cardiac steroids: maintenance of cytotoxicity and loss of cardiac activity of chemically modified derivatives. Int Immunopharmacol 2003;3:1791-801.
34. 2+ increases and apoptosis in androgen-independent, metastatic human prostate adenocarcinoma cells. Cancer Res 2000;60:3807-12.
35. Sarfati M, Mateo V, Baudet S, et al. Sildenafil and vardenafil, types 5 and 6 phosphodiesterase inhibitors, induce caspase-dependent apoptosis of B-chronic lymphocytic leukemia cells. Blood 2003;101:265-9.
36. Pitari GM, Di Guglielmo MD, Park J, Schulz S, Waldman SA. Guanylyl cyclase C agonists regulate progression through the cell cycle of human colon carcinoma cells. Proc Natl Acad Sci U S A 2001;98:7846-51.
37. Drinyaev VA, Mosin VA, Kruglyak EB, et al. Antitumor effect of avermectins. Eur J Pharmacol 2004;501:19-23.
38. Gibson MK, Li Y, Murphy B, et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2005;23:3562-7.
39. Abitbol A, Abdel-Wahab M, Harvey M, et al. Phase II study of tolerance and efficacy of hyperfractionated radiation therapy and 5-fluorouracil, cisplatin, and paclitaxel (taxol) and amifostine (ethyol) in head and neck squamous cell carcinomas: A-3 protocol. Am J Clin Oncol 2005;28:449-55.
40. De Vita VT, Hellman S, Rosenberg SA. CANCER principles and practice of oncology. 7th ed. Vols. 1-2. New York: Lippincott Williams & Wilkins; 2005. p. 3500.
41. Ozoren N, Fisher MJ, Kim K, et al. Homozygous deletion of the death receptor DR4 gene in a nasopharyngeal cancer cell line is associated with TRAIL resistance. Int J Oncol 2000;16:917-25.
42. Brac T. Intracellular polycationic molecules cause reversible swelling of the rough endoplasmic reticulum. Tissue Cell 1983;15:365-73.
43. Brac T. The charge distribution in the rough endoplasmic reticulum/Golgi complex transitional area investigated by microinjection of charged tracers. Tissue Cell 1984;16:859-71.
44. Carew JS, Nawrocki ST, Krupnik YV, et al. Targeting endoplasmic reticulum protein transport: a novel strategy to kill malignant B cells and overcome fludarabine resistance in CLL. Blood 2006;107:222-31.
45. Xu C, Bailly-Maitre B, Reed JC. Endoplasmic reticulum stress: cell life and death decisions. J Clin Invest 2005;115:2656-64.
46. Crompton M. The mitochondrial permeability transition pore and its role in cell death. Biochem J 1999;341:233-49.
47. Takeoka G, Dao L, Wong RY, Lundin R, Mahoney N. Identification of benzethonium chloride in commercial grapefruit seed extracts. J Agric Food Chem 2001;49:3316-20.
48. McDonnell G, Russell AD. Antiseptics and disinfectants: activity, action, and resistance. Clin Microbiol Rev 1999;12:147-79.
49. Coates KM, Flood P. Ketamine and its preservative, benzethonium chloride, both inhibit human recombinant α7 and α4β2 neuronal nicotinic acetylcholine receptors in Xenopus oocytes. Br J Pharmacol 2001;134:871-9.
50. Iorio E, Mezzanzanica D, Alberti P, et al. Alterations of choline phospholipid metabolism in ovarian tumor progression. Cancer Res 2005;65:9369-76.